quinazolines has been researched along with Diffuse Mixed Small and Large Cell Lymphoma in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (7.69) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (15.38) | 29.6817 |
| 2010's | 5 (38.46) | 24.3611 |
| 2020's | 5 (38.46) | 2.80 |
| Authors | Studies |
|---|---|
| Childs, BH; Cisternas, G; Du, T; Garcia-Vargas, J; Huang, F; Liu, W; Mehra, A; Niu, Y; Ping, L; Reschke, S; Song, Y; Sun, Y; Wang, X; Xie, Y; Zhu, J | 1 |
| Childs, BH; Fukuhara, N; Garcia-Vargas, J; Hatake, K; Iriyama, C; Kamezaki, K; Kuroda, J; Kusumoto, S; Makita, S; Maruyama, D; Masuda, S; Minami, H; Nagai, H; Suehiro, Y; Terao, Y; Tobinai, K; Tsujino, T; Tsukamoto, N; Uchida, T; Yanada, M; Yasuda, M | 1 |
| Austin, R; Beckert, V; Childs, BH; Garmann, D; Hiemeyer, F; Mongay Soler, L; Morcos, PN; Moss, J; Zinzani, PL | 1 |
| Cheson, BD; Narkhede, M | 1 |
| Baker, R; Bondarenko, I; Bouabdallah, K; Cao, A; Capra, M; Childs, BH; Feng, J; Galiulin, R; Geissler, K; Hamed, A; Hiemeyer, F; Jin, J; Jurczak, W; Lazaroiu, M; Li, W; Lin, T; Lv, F; Matasar, MJ; Mehra, A; Özcan, M; Sapunarova, K; Saydam, G; Shi, Y; Soler, LM; Szomor, Á; Uchida, T; Wang, MC; Yañez, E; Zhang, Q; Zinzani, PL | 1 |
| Das, M | 1 |
| Markham, A | 1 |
| Cheson, BD; Dreyling, M; Ewer, MS; Farooki, A; Fisher, RI; Goncalves, MD; Lenz, G; O'Brien, S; Yu, A; Zinzani, PL | 1 |
| Appleman, LJ; Beeram, M; Chadha, M; Chu, E; Ejadi, S; Fulk, M; Genvresse, I; Jeffers, M; Lotze, MT; Mountz, JM; Papadopoulos, KP; Patnaik, A; Peña, C; Ramanathan, RK; Rasco, DW; Reif, S; Sachdev, JC; Tolcher, AW; Toledo, FG; Weiss, GJ; Xia, C | 1 |
| Adachi, Y; Furihata, M; Ikezoe, T; Koeffler, HP; Nishioka, C; Takeuchi, T; Yang, J; Yokoyama, A | 1 |
| Bogeschdorfer, F; Gronau, S; Riechelmann, H | 1 |
| Abboud, G; Bertino, JR; Fölsch, E; Gralla, E | 1 |
3 review(s) available for quinazolines and Diffuse Mixed Small and Large Cell Lymphoma
| Article | Year |
|---|---|
Copanlisib in the treatment of non-Hodgkin lymphoma.
Topics: Biomarkers; Clinical Trials as Topic; Disease Management; Disease Susceptibility; Humans; Hyperglycemia; Hypertension; Lymphoma, Non-Hodgkin; Molecular Targeted Therapy; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Prognosis; Pyrimidines; Quinazolines; Signal Transduction; Treatment Outcome | 2020 |
Copanlisib: First Global Approval.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cholangiocarcinoma; Class I Phosphatidylinositol 3-Kinases; Drug Approval; Humans; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Pyrimidines; Quinazolines; Rituximab; United States; United States Food and Drug Administration | 2017 |
[New substances in the therapy of head and neck cancer].
Topics: Administration, Oral; Aminoquinolines; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Basal Cell; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Controlled Clinical Trials as Topic; Double-Blind Method; Erlotinib Hydrochloride; Fibroblast Growth Factor 7; Gefitinib; Head and Neck Neoplasms; Humans; Imiquimod; Infusions, Intravenous; Iodine Radioisotopes; Lung Neoplasms; Lymphatic Metastasis; Lymphoma, Non-Hodgkin; Ointments; Protein Kinase Inhibitors; Quinazolines; Radioimmunotherapy; Randomized Controlled Trials as Topic; Skin Neoplasms; Time Factors; United States; United States Food and Drug Administration | 2006 |
5 trial(s) available for quinazolines and Diffuse Mixed Small and Large Cell Lymphoma
| Article | Year |
|---|---|
A phase I pharmacokinetic study of copanlisib in Chinese patients with relapsed indolent non-Hodgkin lymphoma.
Topics: China; Humans; Lymphoma, Non-Hodgkin; Phosphatidylinositol 3-Kinases; Pyrimidines; Quinazolines | 2022 |
Safety and antitumor activity of copanlisib in Japanese patients with relapsed/refractory indolent non-Hodgkin lymphoma: a phase Ib/II study.
Topics: Antineoplastic Agents; Humans; Lymphoma, Non-Hodgkin; Neoplasm Recurrence, Local; Quinazolines | 2023 |
Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Phosphoinositide-3 Kinase Inhibitors; Pyrimidines; Quinazolines; Recurrence; Rituximab | 2021 |
Preliminary results of a phase II study of single agent Bay 80-6946, a Novel PI3K inhibitor, in patients with relapsed/refractory, indolent or aggressive lymphoma.
Topics: Aged; Antineoplastic Agents; Female; Humans; Lymphoma, Non-Hodgkin; Male; Phosphoinositide-3 Kinase Inhibitors; Pyrimidines; Quinazolines | 2014 |
First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas.
Topics: Administration, Intravenous; Adult; Aged; Class I Phosphatidylinositol 3-Kinases; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Staging; Neoplasms; Pyrimidines; Quinazolines | 2016 |
5 other study(ies) available for quinazolines and Diffuse Mixed Small and Large Cell Lymphoma
| Article | Year |
|---|---|
Copanlisib population pharmacokinetics from phase I-III studies and exposure-response relationships in combination with rituximab.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Humans; Lymphoma, Non-Hodgkin; Pyrimidines; Quinazolines; Rituximab | 2023 |
Copanlisib in heavily pretreated indolent lymphoma.
Topics: Humans; Lymphoma, Non-Hodgkin; Pyrimidines; Quinazolines | 2017 |
Optimal Management of Adverse Events From Copanlisib in the Treatment of Patients With Non-Hodgkin Lymphomas.
Topics: Antineoplastic Agents; Drug-Related Side Effects and Adverse Reactions; Humans; Lymphoma, Non-Hodgkin; Pyrimidines; Quinazolines | 2019 |
Analysis of Aurora B kinase in non-Hodgkin lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Apoptosis; Aurora Kinase B; Aurora Kinases; Caspases; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Enzyme Activation; Humans; JNK Mitogen-Activated Protein Kinases; Lymphoma, Non-Hodgkin; Middle Aged; Organophosphates; Phosphorylation; Protein Serine-Threonine Kinases; Quinazolines; Signal Transduction; Tubulin Modulators; Vincristine; Young Adult | 2009 |
Studies with a 2,4-diamino-5-chloro-quinazoline antifolate: in vitro and invivo correlates in normal and lymphosarcoma dogs.
Topics: Animals; Bone Marrow; Bone Marrow Cells; Deoxyuridine; DNA; DNA, Neoplasm; Dogs; Folic Acid Antagonists; Hydrogen-Ion Concentration; Injections, Intravenous; Leukemia L1210; Lymphoma, Non-Hodgkin; Methotrexate; Quinazolines; Thymine Nucleotides; Time Factors; Tritium | 1971 |